| Progress and challenges towards targeted delivery of cancer therapeutics D Rosenblum, N Joshi, W Tao, JM Karp, D Peer Nature communications 9 (1), 1410, 2018 | 2066 | 2018 |
| CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy D Rosenblum, A Gutkin, R Kedmi, S Ramishetti, N Veiga, AM Jacobi, ... Science advances 6 (47), eabc9450, 2020 | 426 | 2020 |
| Nanoparticles for imaging, sensing, and therapeutic intervention LK Bogart, G Pourroy, CJ Murphy, V Puntes, T Pellegrino, D Rosenblum, ... ACS nano 8 (4), 3107-3122, 2014 | 343 | 2014 |
| A modular platform for targeted RNAi therapeutics R Kedmi, N Veiga, S Ramishetti, M Goldsmith, D Rosenblum, N Dammes, ... Nature nanotechnology 13 (3), 214-219, 2018 | 290 | 2018 |
| Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes N Veiga, M Goldsmith, Y Granot, D Rosenblum, N Dammes, R Kedmi, ... Nature communications 9 (1), 4493, 2018 | 280 | 2018 |
| Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes I Hazan-Halevy, D Rosenblum, S Weinstein, O Bairey, P Raanani, D Peer Cancer letters 364 (1), 59-69, 2015 | 168 | 2015 |
| Omics-based nanomedicine: the future of personalized oncology D Rosenblum, D Peer Cancer letters 352 (1), 126-136, 2014 | 116 | 2014 |
| Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies S Weinstein, IA Toker, R Emmanuel, S Ramishetti, I Hazan-Halevy, ... Proceedings of the National Academy of Sciences 113 (1), E16-E22, 2016 | 105 | 2016 |
| Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target N Veiga, M Goldsmith, Y Diesendruck, S Ramishetti, D Rosenblum, ... Journal of Controlled Release 313, 33-41, 2019 | 58 | 2019 |
| Progress and challenges towards CRISPR/Cas clinical translation D Rosenblum, A Gutkin, N Dammes, D Peer Advanced Drug Delivery Reviews 154, 176-186, 2020 | 51 | 2020 |
| Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles L Kampel, M Goldsmith, S Ramishetti, N Veiga, D Rosenblum, A Gutkin, ... Journal of Controlled Release 337, 378-389, 2021 | 37 | 2021 |
| Roadmap on nanomedicine P Decuzzi, D Peer, D Di Mascolo, AL Palange, PN Manghnani, ... Nanotechnology 32 (1), 012001, 2020 | 30 | 2020 |
| Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines I Hazan-Halevy, D Landesman-Milo, D Rosenblum, S Mizrahy, BD Ng, ... Journal of Controlled Release 244, 149-156, 2016 | 29 | 2016 |
| RNA delivery with a human virus-like particle A Gutkin, D Rosenblum, D Peer Nature Biotechnology 39 (12), 1514-1515, 2021 | 18 | 2021 |
| Resveratrol enhances mRNA and siRNA lipid nanoparticles primary CLL cell transfection E Kon, I Hazan-Halevy, D Rosenblum, N Cohen, S Chatterjee, N Veiga, ... Pharmaceutics 12 (6), 520, 2020 | 17 | 2020 |
| Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro MD Shmueli, L Schnaider, D Rosenblum, G Herzog, E Gazit, D Segal PloS one 8 (6), e66333, 2013 | 17 | 2013 |
| Preclinical proof of principle for orally delivered Th17 antagonist miniproteins S Berger, F Seeger, TY Yu, M Aydin, H Yang, D Rosenblum, ... Cell 187 (16), 4305-4317. e18, 2024 | 12 | 2024 |
| Epithelial–immune crosstalk in health and disease D Rosenblum, S Naik Current opinion in genetics & development 74, 101910, 2022 | 10 | 2022 |
| Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation I Subudhi, P Konieczny, A Prystupa, RL Castillo, E Sze-Tu, Y Xing, ... Immunity, 2024 | 7 | 2024 |
| Systemic modulation of lymphocyte subsets using siRNAs delivered via targeted lipid nanoparticles I Hazan-Halevy, D Rosenblum, S Ramishetti, D Peer RNA Interference and Cancer Therapy: Methods and Protocols, 151-159, 2019 | 5 | 2019 |
Dan PeerProfessor of NanoMedicine and Immunology, Tel Aviv UniversityDirección de correo verificada de post.tau.ac.il
